VasGene - New Therapeutics from Vascular Technology
Site Navigation
Product Pipeline
VasGene is focused initially on the development of patent protected drugs based on its vascular biology expertise, with other potential products in research:
 |
 |
 |
 |
 |
 |
|---|---|---|---|---|---|
| VEGF Antisense | |||||
| Veglin | Cancer |  |
|||
| Veglin + IL-2 | Renal Cell |  |
|||
| Veglin + Alimta/Cisplatinum | Mesothelioma |  |
|||
| Veglin + Gemsar/Carbo | Mesothelioma |  |
|||
| Veglin 2nd Generation | Cancer |  |
|||
| EphB4/sReceptor | |||||
| EphB4 Neutralizing Ab | Cancer |  |
|||
| EphB4 Soluble Receptor | Cancer |  |
|||
| EphB4 Soluble Receptor | AMD |  |
|||
| EphB4 Soluble Receptor | Diabetic eye |  |
|||
| EphB4 RTK Inhibitor | Cancer |  |
|||
| EphB4 RTK Inhibitor | AMD |  |
|||
| Ephrin B2 Agonist | Vascular disease |  |
|||
| VAS 012 | |||||
| VAS 012 Small Molecule | Cancer |  |
|||